Marc Miravitlles Fernández I’m a specialist in Respiratory Medicine trained at Vall d’Hebron Hospital in Barcelona. My focus is on clinical research in chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD) with the objective to find a cure and improve the quality of life of patients suffering these chronic respiratory diseases. Institutions of which they are part Main researcher Pneumology Vall Hebron Institut de Recerca Doctor Pneumology General Hospital Twitter Email Marc Miravitlles Fernández Twitter Email Institutions of which they are part Main researcher Pneumology Vall Hebron Institut de Recerca Doctor Pneumology General Hospital I’m a specialist in Respiratory Medicine trained at Vall d’Hebron Hospital in Barcelona. My focus is on clinical research in chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD) with the objective to find a cure and improve the quality of life of patients suffering these chronic respiratory diseases.
I’m a Pulmonologist and Senior Researcher at the Vall d’Hebron University Hospital and the Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain. I obtained my MD at the Universitat de Barcelona, Barcelona, Spain in 1986 and my PhD at the Universitat Autònoma de Bacelona in 1997. I trained as specialist in Respiratory Medicine at Vall d'Hebron Hospital. My primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. I served as Secretary General of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) from 1999 to 2003 and I was responsible for International Relationships of SEPAR from 2006 until 2012. I was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and I was the Guidelines Director of the ERS from 2015 to 2018. I have acted as a consultant and/or chair or author for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on diagnostic and treatment of exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. I am also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present) and coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012). I am the director of the reference center for diagnosis and treatment of AATD in the Hospital Vall d’Hebron and I am author of 498 publications listed in PubMed and a h-index of 73 (May 2020)
Projects Detección rápida del alelo deficitario de la alfa-1 antitripsina Mmalton mediante PCR a tiempo real y curva de fusión. IP: - Collaborators: Esther Rodríguez González, Marc Miravitlles Fernández, Miriam Barrecheguren Fernández Funding agency: Fundació Catalana de Pneumologia Funding: 12000 Reference: 2014\FUCAP-GRIFOLS\RODRIGUEZ Duration: 01/06/2014 - 31/05/2017 Pneumologia (GRC) IP: - Collaborators: Esther Rodríguez González, Sergi Martí Beltran, María Jose Jurado Luque, Marc Miravitlles Fernández, Ana Villar Gomez, Antonio Román Broto, Antonio Álvarez Fernandez, Victor Monforte Torres, Odile Romero Santo-Tomas, Sonia Lopez Rodriguez, Montserrat Murillo Andres, Miriam Barrecheguren Fernández, Carles Bravo Masgoret, Mario Culebras Amigo, Fco. Javier Muñoz Gall, Gabriel Sampol Rubio, Jaume Ferrer Sancho, Maria Antonia Ramon Belmonte, Rosa Lloria Verges, Mercedes Pallero Castillo, Mª Jesús Cruz Carmona, Cristina Berastegui Garcia, Manuel López Meseguer, Susana Gómez Olles, Berta Saez Gimenez, Iñigo Ojanguren Arranz Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: Reference: 2014 SGR 523 Duration: 01/01/2014 - 31/12/2016 Alpha-1 International Registry IP: Marc Miravitlles Fernández Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 263446 Reference: QLG2-2001-01021 Duration: 01/01/2002 - 01/01/2005 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3
